Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2000

View Archived Issues

Mixed Y1 antagonist/Y4 agonist 1229U91 examined in rats and Y1 knockout mice

Drug screening technology company emerges from NeuroSearch

Selective 5-HT7 receptor antagonist SB-269970-A characterized

Flibanserin reduces anxiety without locomotor effects in rat model

GPC Biotech and Karo Bio to develop novel antibiotics

Novo Nordisk and AHP settle Activella patent dispute

Matrix submits second part of NDA for IntraDose

InterMune acquires additional rights to Actimmune

U.S. affiliates of Takeda establish strategic merger agreement

AmBisome approved in U.S. for cryptococcal meningitis in AIDS patients

British Biotech announces preliminary results for year ending in April 2000

Drug discovery collaboration between Pharmacia and Pharmacopeia restructured

Organon's fertility treatment now available in Germany

Abbott seeks E.U. approval for lopinavir as HIV therapy

Cell Pathways to market Nilandron to urologists

Immunex licenses prostate cancer-derived antigens from UroCor

Newly discovered inhibitor of pestivirus replication may lead to new treatments for HCV

Hepatoprotective effects of ZNC-2381 described in several experimental models

Combination of natural ingredients as a potential new treatment for prostatitis

OC144-093 characterized as a novel inhibitor of P-gp-mediated MDR in vitro and in vivo

R-848 potently modulates IgE synthesis in PBMCs from normal and allergic donors

Methylprednisolone derivative P-4114 effective against allergic bronchoconstriction in guinea pigs

FDA approves Sarafem for treatment of premenstrual dysphoric disorder

Novel guanylate cyclase activators designed at Aventis

Several newly issued patents cover related series of smooth muscle cell proliferation inhibitors

Lilly's new 5-HT-modulating compounds useful for CNS disorders

Antagonists of platelet adhesion receptor in development at Merck as antithrombotics

Xenoxins identified at Transgene as new agents for arrhythmias, CF and hormonal imbalance

New cationic lipids useful for nonviral gene delivery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...